Literature DB >> 29345976

Synthetic Biology: Immunotherapy by Design.

Jamie Brenner1, Jang Hwan Cho1, Nicole M L Wong1, Wilson W Wong1.   

Abstract

Cellular immunotherapy holds great promise for the treatment of human disease. Clinical evidence suggests that T cell immunotherapies have the potential to combat cancers that evade traditional immunotherapy. Despite promising results, adverse effects leading to fatalities have left scientists seeking tighter control over these therapies, which is reflected in the growing body of synthetic biology literature focused on developing tightly controlled, context-independent parts. In addition, researchers are adapting these tools for other uses, such as for the treatment of autoimmune disease, HIV infection, and fungal interactions. We review this body of work and devote special attention to approaches that may lend themselves to the development of an "ideal" therapy: one that is safe, efficient, and easy to manufacture. We conclude with a look toward the future of immunotherapy: how synthetic biology can shift the paradigm from the treatment of disease to a focus on wellness and human health as a whole.

Entities:  

Keywords:  autoimmune disease; cancer; cellular immunotherapy; genetic circuits; infectious disease; synthetic biology

Mesh:

Substances:

Year:  2018        PMID: 29345976     DOI: 10.1146/annurev-bioeng-062117-121147

Source DB:  PubMed          Journal:  Annu Rev Biomed Eng        ISSN: 1523-9829            Impact factor:   9.590


  11 in total

1.  BTBBCL6 dimers as building blocks for reversible drug-induced protein oligomerization.

Authors:  Lena Nitsch; Patrizia Jensen; Hojong Yoon; Jonas Koeppel; Shourya Sonkar Roy Burman; Eric Sebastian Fischer; Claudia Scholl; Stefan Fröhling; Mikołaj Słabicki
Journal:  Cell Rep Methods       Date:  2022-04-13

2.  Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide.

Authors:  Max Jan; Irene Scarfò; Rebecca C Larson; Amanda Walker; Andrea Schmidts; Andrew A Guirguis; Jessica A Gasser; Mikołaj Słabicki; Amanda A Bouffard; Ana P Castano; Michael C Kann; Maria L Cabral; Alexander Tepper; Daniel E Grinshpun; Adam S Sperling; Taeyoon Kyung; Quinlan L Sievers; Michael E Birnbaum; Marcela V Maus; Benjamin L Ebert
Journal:  Sci Transl Med       Date:  2021-01-06       Impact factor: 17.956

3.  Engineering light-controllable CAR T cells for cancer immunotherapy.

Authors:  Ziliang Huang; Yiqian Wu; Molly E Allen; Yijia Pan; Phillip Kyriakakis; Shaoying Lu; Ya-Ju Chang; Xin Wang; Shu Chien; Yingxiao Wang
Journal:  Sci Adv       Date:  2020-02-19       Impact factor: 14.136

Review 4.  Engineering precision therapies: lessons and motivations from the clinic.

Authors:  Mingqi Xie; Mirta Viviani; Martin Fussenegger
Journal:  Synth Biol (Oxf)       Date:  2020-11-24

5.  Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol.

Authors:  Linfeng Yang; Jianli Yin; Jiali Wu; Longliang Qiao; Evan M Zhao; Fengfeng Cai; Haifeng Ye
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-24       Impact factor: 11.205

6.  Robust and tunable signal processing in mammalian cells via engineered covalent modification cycles.

Authors:  Ross D Jones; Yili Qian; Katherine Ilia; Benjamin Wang; Michael T Laub; Domitilla Del Vecchio; Ron Weiss
Journal:  Nat Commun       Date:  2022-03-31       Impact factor: 17.694

Review 7.  Chimeric antigen receptor- and natural killer cell receptor-engineered innate killer cells in cancer immunotherapy.

Authors:  Cai Zhang; Yuan Hu; Weihua Xiao; Zhigang Tian
Journal:  Cell Mol Immunol       Date:  2021-07-15       Impact factor: 22.096

8.  Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients.

Authors:  Long-Qing Li; Liang-Hao Zhang; Yan Zhang; Xin-Chang Lu; Yi Zhang; Yong-Kui Liu; Manhas Abdul Khader; Jia-Zhen Li
Journal:  Aging (Albany NY)       Date:  2020-11-16       Impact factor: 5.682

9.  DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation.

Authors:  Xiao Huang; Jasper Z Williams; Ryan Chang; Zhongbo Li; Cassandra E Burnett; Rogelio Hernandez-Lopez; Initha Setiady; Eric Gai; David M Patterson; Wei Yu; Kole T Roybal; Wendell A Lim; Tejal A Desai
Journal:  Nat Nanotechnol       Date:  2020-12-14       Impact factor: 40.523

10.  Development of an immune-related prognostic index associated with hepatocellular carcinoma.

Authors:  Bo Hu; Xiao-Bo Yang; Xin-Ting Sang
Journal:  Aging (Albany NY)       Date:  2020-03-19       Impact factor: 5.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.